TARSUS PHARMACEUTICALS, INC. (TARS) Operating Margin
- Operating margin · 12 months: Value -8.00%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -8.00% | Operating income / revenue. Period ending 2026-06-30. $-48.53M ÷ $606.33M × 100 ≈ -8.00% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -48.53M USD | Operating Income (Loss) |
| Revenue | 606.33M USD | |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 87.68M USD | Research and Development Expense |
| Selling, general and administration | 526.44M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-48.53M | $606.33M | (m) | $87.68M | $526.44M | -8.00% |
| 2026-03-31 | $-50.81M | $535.08M | (m) | $72.26M | $478.76M | -9.50% |
| 2025-12-31 | $-70.97M | $451.36M | (m) | $64.32M | $427.32M | -15.72% |
| 2025-09-30 | $-87.41M | $366.10M | (m) | $63.16M | $365.67M | -23.88% |
| 2025-06-30 | $-98.05M | $295.52M | (m) | $59.00M | $314.95M | -33.18% |
| 2025-03-31 | $-109.17M | $233.67M | (m) | $55.73M | $270.73M | -46.72% |
| 2024-12-31 | $-120.57M | $182.95M | (m) | $53.39M | $237.31M | -65.90% |
| 2024-09-30 | $-140.60M | $129.62M | (m) | $49.82M | (m) | -108.47% |
| 2024-06-30 | $-156.37M | $83.37M | (m) | $49.80M | (m) | -187.55% |
| 2024-03-31 | $-155.89M | $42.56M | (m) | $50.02M | (m) | -366.27% |
| 2023-12-31 | $-143.16M | $17.45M | (m) | $50.31M | $108.70M | -820.53% |
| 2023-09-30 | $-113.77M | $14.37M | (m) | $47.03M | (m) | -791.66% |
| 2023-06-30 | $-95.74M | (m) | (m) | $45.84M | (m) | (m) |
| 2023-03-31 | $-68.14M | (m) | (m) | $42.90M | (m) | (m) |
| 2022-12-31 | $-62.71M | $25.82M | (m) | $42.62M | (m) | -242.92% |
| 2022-09-30 | $-62.10M | $16.15M | (m) | $40.63M | (m) | -384.42% |
| 2022-06-30 | $-54.90M | $17.39M | (m) | $39.93M | (m) | -315.61% |
| 2022-03-31 | $-42.39M | $24.13M | (m) | $37.53M | (m) | -175.65% |
| 2021-12-31 | $-12.16M | $57.03M | (m) | $41.71M | (m) | -21.32% |
| 2021-09-30 | $-9.19M | (m) | (m) | $41.26M | (m) | (m) |
| 2021-06-30 | $-3.62M | (m) | (m) | $39.04M | (m) | (m) |
| 2021-03-31 | $-14.17M | (m) | (m) | $33.58M | (m) | (m) |
| 2020-12-31 | $-27.00M | (m) | (m) | $18.83M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-4.30M | (m) | (m) | $3.16M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |